

REGIONAL PATHOLOGY SERVICES

Regional Pathology Services University of Nebraska Medical Center 981180 Nebraska Medical Center Omaha, Nebraska 68198-1180 www.reglab.org

Toll Free: 1.800.334.0459 Phone: 402.559.6420 FAX: 402.559.9497

HEMATOPATHOLOGY CONSULTATION TEST REQUEST FORM

SHADED AREAS FOR PATIENT INFORMATION REQI	UIRED									
PATIENT LAST NAME	FIRST NAME		MI	COLL	ECTION DATE		TIME	REPORT	STAT	
DOD OFFICE D	T. ID# / ADDITIONAL INFO			mm	dd yy		AM/ PM	FAX		
DOB GENDER MALE mm dd yyyy				PH	PHYSICIAN:					
SSN BILL OFFICE/CLIENT				Pho	Phone: Fax:					
- -				PA1	PATHOLOGIST:					
PATIENT INSURANCE ATTACH COPY OF FRONT AND BACK OF INSURANCE CARD AND ATTACH COPY OF FRONT OF DI IF UNABLE TO OBTAIN COPY OF REQUIRED INFORMATION ALL FIELDS BELOW ARE RE			RIVERS LICENS	E Pho	ne:		Fax:			
GUARANTOR NAME/DOB (REQUIRED IF PATIENT IS A MINOR)				Acc	ount Numbe	er				
ADDRESS	CITY	STATE	ZIP	Acc	ount Name			 		
PRIMARY INSURANCE MEDICARE IN-PATIENT MEDICARE OUT-PATIENT MEDICAID			☐ INSURANC							
POLICY ID# GROUP ID#			INCORANC	Add	Iress					
INSURANCE COMPANY PHON		PHONE NU	IMBER	City	1		State		Zip	
INSURANCE COMPANY ADDRESS	CITY	STATE	ZIP	Pho Fax	one:		_			
				ı ax						
EFFECTIVE DATE / /					N ATTACHED		R AUTHORIZAT			
ICD-10 #1 ICD-10 #2	ICD-10 #	# 3		ONLY OF THAN FO	WHEN ORDERING TE RDER TESTS THAT ARI OR SCREENING PURP	STS FOR WHICH M E MEDICALLY NECE OSES. FOR MORE I	EDICARE REIMBURSE ESSARY FOR THE DIAC NFORMATION SEE reg	EMENT WILL BE SOU GNOSIS OR TREATM glab.org/billingcomplian	GHT, PHYSICIANS SHOULD IENT OF A PATIENT RATHER nce/	
Please provide complete informati										
NOTICE: Additional reference laboratory testing may be r testing from the reference laboratory. Check the box if ac	required at the discretion of the path Iditional reference laboratory testing	ologist to esta g is not desire	ablish or confirm d. Please note that	a diagnosis. a definitive d	If additional testin iagnosis may not	ng is needed the be possible.	e client or patient r	may receive an i	nvoice for additional	
ANALYSIS REQUESTED			PATIENT HISTORY AND PERTINENT LAB DATA							
Slide Consultation			Specify:							
☐ Bone Marrow Evaluation☐ Lymph Node/Tissue Evaluation										
Conventional Cytogenetics										
☐ FISH Cytogenetics										
Specify:			_							
			D	IAGNO	STIC HIS	STORY/S	SUSPECT	ED DIA	GNOSIS	
Molecular Studies	e (p210 & p190, for diagnosis))	Lymphoma	1		STORY/S	SUSPECT	ED DIA	GNOSIS	
Molecular Studies BCR/ABL1 Translocation, Qualitative BCR/ABL1 Translocation, Quantitative			_	ı lodgkin L	ymphona	STORY/S	SUSPECT	ED DIA	GNOSIS	
Molecular Studies BCR/ABL1 Translocation, Qualitative BCR/ABL1 Translocation, Quantitative BRAF Mutation (p.V600E)	Ve (p210 only, for therapy monitori		Lymphoma Non-H Hodgk	a lodgkin L in Lymph le Myelor	ymphona ioma	STORY/S	SUSPECT	ED DIAG	GNOSIS	
Molecular Studies BCR/ABL1 Translocation, Qualitative BCR/ABL1 Translocation, Quantitative BRAF Mutation (p.V600E) FLT3 Mutation (Internal Tandem Dup NPM1 Mutation	Ve (p210 only, for therapy monitori		Lymphoma Non-H Hodgk Multip Unkno	a lodgkin L in Lymph le Myelor	ymphona ioma	STORY/S	SUSPECT	ED DIAC	GNOSIS	
Molecular Studies BCR/ABL1 Translocation, Qualitative BCR/ABL1 Translocation, Quantitative BRAF Mutation (p.V600E) FLT3 Mutation (Internal Tandem Dup NPM1 Mutation IDH1 and IDH2 Mutation	ve (p210 only, for therapy monitori		Lymphoma Non-F Hodgk Multip Unkno	a lodgkin L iin Lymph le Myelor wn Type	ymphona noma na		SUSPECT	ED DIAG	GNOSIS	
Molecular Studies BCR/ABL1 Translocation, Qualitative BCR/ABL1 Translocation, Quantitative BRAF Mutation (p.V600E) FLT3 Mutation (Internal Tandem Dup NPM1 Mutation IDH1 and IDH2 Mutation PML/RARA translocation by RT-PCF (non-quantitative, for Minimal Residual Disease)	ve (p210 only, for therapy monitorion of the properties of the pro		Lymphoma Non-F Hodgk Multip Unkno Leukemia: Acute Chron	a lodgkin L lin Lymph le Myelor wn Type Lymphol ic Lymph	ymphona noma na olastic Leuke ocytic Leuke	emia emia	SUSPECT	ED DIAC	GNOSIS	
Molecular Studies BCR/ABL1 Translocation, Qualitative BCR/ABL1 Translocation, Quantitative BRAF Mutation (p.V600E) FLT3 Mutation (Internal Tandem Dup NPM1 Mutation IDH1 and IDH2 Mutation PML/RARA translocation by RT-PCF (non-quantitative, for Minimal Residual Disease) IgH Heavy Chain Gene Rearrangem	ve (p210 only, for therapy monitorion of the properties of the pro		Lymphoma Non-F Hodgk Multip Unkno Leukemia: Acute Chron Acute	lodgkin L in Lymph le Myelor wn Type Lymphol ic Lymph Myeloge	ymphona noma na olastic Leuke ocytic Leuke nous Leuke	emia emia mia	SUSPECT	ED DIAC	GNOSIS	
Molecular Studies BCR/ABL1 Translocation, Qualitative BCR/ABL1 Translocation, Quantitative BRAF Mutation (p.V600E) FLT3 Mutation (Internal Tandem Dup NPM1 Mutation IDH1 and IDH2 Mutation PML/RARA translocation by RT-PCF (non-quantitative, for Minimal Residual Disease) IgH Heavy Chain Gene Rearrangem JAK2 (p.V617F) Mutation CALR mutation	ve (p210 only, for therapy monitorion of the properties of the pro		Lymphoma	lodgkin Lin Lymph le Myelor wn Type Lymphol ic Lymph Myeloge ic Myelog	ymphona noma olastic Leuke ocytic Leuke nous Leuke genous Leuke	emia emia mia	SUSPECT	ED DIAC	GNOSIS	
Molecular Studies BCR/ABL1 Translocation, Qualitative BCR/ABL1 Translocation, Quantitative BRAF Mutation (p.V600E) FLT3 Mutation (Internal Tandem Dup NPM1 Mutation IDH1 and IDH2 Mutation PML/RARA translocation by RT-PCF (non-quantitative, for Minimal Residual Disease) IgH Heavy Chain Gene Rearrangem JAK2 (p.V617F) Mutation CALR mutation MPL mutation	ve (p210 only, for therapy monitorion of the part of t		Lymphoma Non-F Hodgk Multip Unknot Leukemia: Acute Chron Acute Chron Hairy Myelo	lodgkin L in Lymph le Myelor wn Type Lymphob ic Lymph Myeloge ic Myelog Cell Leuk dysplasti	ymphona noma olastic Leuke ocytic Leuke nous Leuke genous Leuk emia c Syndrome	emia emia mia kemia	SUSPECT	ED DIAC	GNOSIS	
Molecular Studies BCR/ABL1 Translocation, Qualitative BCR/ABL1 Translocation, Quantitative BRAF Mutation (p.V600E) FLT3 Mutation (Internal Tandem Dup NPM1 Mutation IDH1 and IDH2 Mutation PML/RARA translocation by RT-PCF (non-quantitative, for Minimal Residual Disease) IgH Heavy Chain Gene Rearrangem JAK2 (p.V617F) Mutation CALR mutation MPL mutation KIT p.D816 mutation (for Systemic M	ve (p210 only, for therapy monitorion) Rement Mastocytosis)		Lymphoma Non-F Hodgk Multip Unknot Leukemia: Acute Chron Acute Hairy Myelo	lodgkin L in Lymph le Myelor wn Type Lymphob ic Lymph Myeloge ic Myeloge ic Myeloge ic Myeloge jc Gell Leuk dysplasti	ymphona noma plastic Leuke ocytic Leuke nous Leuke genous Leuk emia c Syndrome ve Disorder	emia emia mia kemia	SUSPECT	ED DIAC	GNOSIS	
Molecular Studies BCR/ABL1 Translocation, Qualitative BCR/ABL1 Translocation, Quantitative BRAF Mutation (p.V600E) FLT3 Mutation (Internal Tandem Dup NPM1 Mutation IDH1 and IDH2 Mutation PML/RARA translocation by RT-PCF (non-quantitative, for Minimal Residual Disease) IgH Heavy Chain Gene Rearrangem JAK2 (p.V617F) Mutation CALR mutation MPL mutation KIT p.D816 mutation (for Systemic M	ve (p210 only, for therapy monitorion of particular only) Research Mastocytosis) e Rearrangement		Lymphoma Non-F Non-F Hodgk Multip Unkno Leukemia: Chron Acute Chron Hairy Myelo Myelo	lodgkin L in Lymph le Myelor wn Type Lymphob ic Lymph Myeloge ic Myelog Cell Leuk dysplasti proliferati wn Type	ymphona noma plastic Leuke ocytic Leuke nous Leuke genous Leuk emia c Syndrome ve Disorder	emia emia mia kemia	SUSPECT	ED DIAC	GNOSIS	
Molecular Studies BCR/ABL1 Translocation, Qualitative BCR/ABL1 Translocation, Quantitative BRAF Mutation (p.V600E) FLT3 Mutation (Internal Tandem Dup NPM1 Mutation IDH1 and IDH2 Mutation PML/RARA translocation by RT-PCF (non-quantitative, for Minimal Residual Disease) IgH Heavy Chain Gene Rearrangem JAK2 (p.V617F) Mutation CALR mutation MPL mutation KIT p.D816 mutation (for Systemic MT-Cell Receptor Gamma Chain Gene	ve (p210 only, for therapy monitorion of particular only) Research Mastocytosis) e Rearrangement		Lymphoma Non-F Non-F Hodgk Multip Unkno Leukemia: Chron Acute Chron Hairy Myelo Unkno Other Diag	lodgkin L in Lymph le Myelor wn Type Lymphobic Lymph Myeloge ic Myelog Cell Leuk dysplasti proliferati wn Type nosis: tatic Tum	ymphona noma na olastic Leuke ocytic Leuke nous Leuke genous Leuk emia c Syndrome ve Disorder	emia emia mia kemia	SUSPECT	ED DIAC	GNOSIS	
Molecular Studies BCR/ABL1 Translocation, Qualitative BCR/ABL1 Translocation, Quantitative BRAF Mutation (p.V600E) FLT3 Mutation (Internal Tandem Dup NPM1 Mutation IDH1 and IDH2 Mutation PML/RARA translocation by RT-PCF (non-quantitative, for Minimal Residual Disease) IgH Heavy Chain Gene Rearrangem JAK2 (p.V617F) Mutation CALR mutation MPL mutation KIT p.D816 mutation (for Systemic MT-Cell Receptor Gamma Chain Gene	ve (p210 only, for therapy monitorion of particular only) Research Mastocytosis) e Rearrangement		Lymphoma Non-F Hodgk Multip Unknote Acute Chron Acute Chron Hairy Myelo Unknote Other Diag Aplast	lodgkin L in Lymph le Myelor wn Type Lymphobic Lymph Myeloge ic Myelog Cell Leuk dysplasti proliferati wn Type nosis: tatic Tum ic Anemi	ymphona noma na plastic Leuke ocytic Leuke nous Leuke nous Leuke mia c Syndrome ve Disorder or	emia emia mia kemia	SUSPECT	ED DIAC	GNOSIS	
Molecular Studies	ve (p210 only, for therapy monitorion plication) Rement Mastocytosis) e Rearrangement C Evaluation*		Lymphoma Non-F Hodgk Multip Unknot Acute Chron Acute Chron Hairy Myelo Unknot Other Diag Aplast Immui	lodgkin L in Lymph le Myelor wn Type Lymphob ic Lymph Myeloge ic Myelog Cell Leuk dysplasti proliferati wn Type nosis: tatic Tum ic Anemia	ymphona noma na plastic Leuke ocytic Leuke nous Leuke nous Leuke mia c Syndrome ve Disorder or	emia emia mia kemia	SUSPECT	ED DIAC	GNOSIS	
Molecular Studies	ve (p210 only, for therapy monitorion of polication) Rement Mastocytosis) e Rearrangement C Evaluation* essment*		Lymphoma Non-F Hodgk Multip Unknot Acute Chron Acute Chron Hairy Myelo Unknot Other Diag Aplast Immui	lodgkin L in Lymph le Myelor wn Type Lymphob ic Lymph Myeloge ic Myelog Cell Leuk dysplasti proliferati wn Type nosis: tatic Tum ic Anemia	ymphona noma na plastic Leuke ocytic Leuke nous Leuke genous Leuk emia c Syndrome ve Disorder or a ncy	emia emia mia kemia			GNOSIS	
Molecular Studies	ve (p210 only, for therapy monitorion of polication) Rement Mastocytosis) e Rearrangement C Evaluation* essment*		Lymphoma Non-H Hodgk Multip Unknot Ceukemia: Acute Chron Hairy Myelo Unknot Other Diag Metas Aplast Immui Other:	lodgkin L in Lymph le Myelor wn Type Lymphob ic Lymph Myeloge ic Myelog Cell Leuk dysplasti proliferati wn Type nosis: tatic Tum ic Anemia	ymphona noma na plastic Leuke ocytic Leuke nous Leuke nous Leuke emia c Syndrome ve Disorder or a ncy	emia emia mia kemia	— MENT HIST	TORY		
Molecular Studies	ve (p210 only, for therapy monitorion of polication) Research Mastocytosis) e Rearrangement c Evaluation* essment* al		Lymphoma Non-H Hodgk Multip Unknot Ceukemia: Acute Chron Hairy Myelo Unknot Myelo Unknot Other Diag Metas Aplast Immur Other: Chem	lodgkin L in Lymph le Myelor wn Type Lymphot ic Lymph Myeloge ic Myelog Cell Leuk dysplasti proliferati wn Type nosis: tatic Tum ic Anemia nodeficier	ymphona noma na plastic Leuke ocytic Leuke nous Leuke genous Leuke genous Leuke or a ncy RECENT	emia emia mia kemia TREATI	— MENT HIST	TORY □ Antibod	y	
Molecular Studies	ve (p210 only, for therapy monitorion of polication) Repent Mastocytosis) e Rearrangement c Evaluation* essment* al		Lymphoma Non-H Hodgk Multip Unknot Ceukemia:	lodgkin Lin Lymphe Myeloge ic Mye	ymphona noma na plastic Leuke ocytic Leuke nous Leuke genous Leuke genous Leuk emia c Syndrome ve Disorder or a ncy RECENT	emia emia mia kemia TREATI radiation ologous Bi	─ MENT HIS T MT/PSCT	TORY □ Antibod		
Molecular Studies	ve (p210 only, for therapy monitorion of polication) Research Mastocytosis) e Rearrangement c Evaluation* essment* al	ing)	Lymphoma Non-H Hodgk Multip Unknot Ceukemia: Chron Acute Chron Hairy Myelo Unknot Myelo Unknot Other Diag Metas Aplast Immun Other: Chem Growt	lodgkin Lin Lymphie Myelor wn Type Lymphobic Lymph Myeloge ic Myelog Cell Leuk dysplastion Type nosis: tatic Tumic Anemianodeficier otherapy h Factor	ymphona noma na plastic Leuke ocytic Leuke nous Leuke nous Leuke emia c Syndrome ve Disorder or a ncy RECENT	emia emia mia kemia TREATM	 MENT HIST MT/PSCT	TORY □ Antibod □ Allogen	y eic BMT/PSCT	
Molecular Studies	ve (p210 only, for therapy monitorion of polication) R ment Mastocytosis) e Rearrangement c Evaluation* essment* al N TYPE one Marrow Aspirate one Marrow Particles/C	ing)	Lymphoma Non-H Hodgk Multip Unknot Chron Acute Chron Hairy Myelo Unknot Myelo Unknot Other Diag Metas Aplast Immun Other: Chem Growt Other:	lodgkin Lin Lymphie Myelor Lymphotic Lymphotic Lymph Myeloge ic Myelog Cell Leuk dysplastion of the control of	ymphona noma noma nolastic Leuke ocytic Leuke nous Leuke genous Leuke genous Leuk enia c Syndrome ve Disorder or a ncy RECENT Aut	emia emia mia kemia TREATI radiation cologous Bi	MT/PSCT	TORY □ Antibod □ Allogen	y eic BMT/PSCT	
Molecular Studies	ve (p210 only, for therapy monitorion of polication) R ment Mastocytosis) e Rearrangement c Evaluation* essment* al N TYPE one Marrow Aspirate one Marrow Particles/C	lot	Lymphoma Non-H Hodgk Multip Unknot Chron Acute Chron Hairy Myelo Unknot Myelo Unknot Other Diag Metas Aplast Immun Other: Chem Growt Other:	lodgkin Lin Lymphie Myelor Lymphotic Lymphotic Lymph Myeloge ic Myelog Cell Leuk dysplastion of the control of	ymphona noma noma nolastic Leuke ocytic Leuke nous Leuke genous Leuke genous Leuk enia c Syndrome ve Disorder or a ncy RECENT Aut	emia emia mia kemia TREATI radiation cologous Bi	MT/PSCT	TORY □ Antibod □ Allogen	y eic BMT/PSCT	
Molecular Studies	ve (p210 only, for therapy monitorion of polication) Research Mastocytosis) Re Rearrangement C Evaluation* Ressment* Ressment* Response Marrow Aspirate Cone Marrow Particles/C	lot	Lymphoma Non-H Hodgk Multip Unknot Chron Acute Chron Hairy Myelo Unknot Myelo Unknot Other Diag Metas Aplast Immun Other: Chem Growt Other:	lodgkin Lin Lymphie Myelor Lymphotic Lymphotic Lymph Myeloge ic Myelog Cell Leuk dysplastion of the control of	ymphona noma noma nolastic Leuke ocytic Leuke nous Leuke genous Leuke genous Leuk enia c Syndrome ve Disorder or a ncy RECENT Aut	emia emia mia kemia TREATI radiation cologous Bi	MT/PSCT	TORY □ Antibod □ Allogen	y eic BMT/PSCT	
Molecular Studies	ve (p210 only, for therapy monitorion of polication) Research Restrangement C Evaluation* essment* al N TYPE one Marrow Aspirate one Marrow Particles/C	lot	Lymphoma Non-H Hodgk Multip Unknot Chron Acute Chron Hairy Myelo Unknot Myelo Unknot Other Diag Metas Aplast Immun Other: Chem Growt Other:	lodgkin Lin Lymphie Myelor Lymphotic Lymphotic Lymph Myeloge ic Myelog Cell Leuk dysplastion of the control of	ymphona noma noma nolastic Leuke ocytic Leuke nous Leuke genous Leuke genous Leuk enia c Syndrome ve Disorder or a ncy RECENT Aut	emia emia mia kemia TREATI radiation cologous Bi	MT/PSCT	TORY □ Antibod □ Allogen	y eic BMT/PSCT	



Hematopathology Requests

Note: Specimens are time and temperature sensitive. Include a recent CBC and differential with the test request. RPMI preservative available from Regional Pathology Services.

If test needs to be performed on the weekends, call to schedule with Regional Pathology Services, 402-559-6420 or 1-800-334-0459

RPS after hours pager: 402-888-2086

Flow Cytometry Information

Hours: Monday-Saturday: 0730-1700. Sunday: On-call 0730-1700 (Pager: 888-5905)

Bone Marrow Lab Information

Hours: Monday-Friday 0730-1700 (Pager 402-888-0109)

Testing Supplies

Regional Pathology Services furnishes specimen-collection supplies for use by clients that send tests to us.

Supplies are ordered online at reglab.org/customer-service/supply-orders/testing supplies and log-on information may be obtained by calling client services

Toll Free: 800-334-0459 Phone: 402-559-6420

Courier Services

Regional Pathology Services offers an extensive courier network, which includes contracted land and air courier services. Contracted land specimen pickup is provided at no charge for specimens tested by Regional Pathology Services or our designated reference laboratories.

To inquire about scheduled stops and after hours courier service, call client services Toll Free 800-334-0459 Phone 402-559-6420

If shipping specimens address to: Regional Pathology Services University of Nebraska Medical Center 668 S 41st St., MSB 3500 Omaha. NE 68105-1180

Transport Instructions:

Specimen Handling/Shipping

To ensure the safety of personnel and the community, proper handling of specimens for shipment is mandatory. Specimens will be rejected if submitted improperly. The shipper is responsible for the proper packaging and shipping of all specimens. Shippers must be trained and certified by their employer to be able to prepare and ship packages containing diagnostic specimens, biological substances and infectious substances. Rules of the various agencies involved may differ, and may change regularly. Specimen must have at least two patient identifiers and be packaged in sealed plastic bags to prevent leakage or contamination. Place accompanying paperwork in the bag pocket, away from the specimen. Practice universal blood and body fluid precautions when handling specimens.

For tests that require scheduling or special arrangements prior to specimen collection, refer to the Online Test Menu at reglab.org for more information.

Questions?

Contact client services at 800-334-0459